Skip to main content

Table 1 Clinical characteristics of all studied mCRPC patients prior to PSMA-RLT therapy

From: Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

ParametersValues
Patients (n)54
Age (mean ± SD)72 ± 7 years
Weight (mean ± SD)82 ± 13 kg
[177Lu]Lu-PSMA-617 (mean ± SD)7315 ± 573 MBq
Karnofsky score (n)
  < 80%
  ≥ 80%
(18) 33 %
(36) 67 %
ECOG-Index (n)
  0
  1
  2
(1) 2 %
(49) 90 %
(4) 8 %
Patients with previous enzalutamid/abirateron69 %
Patients with previous docetaxel/cabazitaxel67 %
Metastatic lesions (n)
  Bone
  Local recurrence + lymph node
  Bone + lymph node
  Bone + lymph node + liver
  Bone + lymph node + lung
(15) 27.7%
(8) 14.8%
(22) 40.7%
(5) 9.2%
(4) 7.4%